Key Takeaways
- Record profit, broad-based execution: Highest ever quarterly profit on standalone and consolidated basis, driven by record Xanthine volumes, best-ever API revenue, and a step-up in CDMO/CMO sales.
- Xanthine pricing pressure persists but volume compensates: Spot caffeine prices softened over $1/kg on Chinese competition, yet absolute gross profit contribution grew because facilities ran near full capacity.
- CDMO/CMO inflection arriving: Two new customers added this quarter; FY25 sales will exceed last year's Rs.170 crores, and management expects FY26 to be "significantly higher" on a pipeline that is already converting into a sizable order book.
- Margins jumped on mix and one-offs: Standalone EBITDA margin reached ~24%, up 200–300 bps QoQ, helped by a surge in higher-margin CDMO/CMO sales, solar energy savings, and Rs.7 crore of dividend income.
- What to watch next quarter: Whether the record margin can sustain without the dividend tailwind, the pace of CDMO order book conversion, and the FY26–28 guidance reset promised on the Q4 call.
Xanthine Derivatives: Volume Offsets Price, Mix Shift Underway
- Record volumes despite pricing headwind: Quarterly volume sales hit an all-time high even as spot market prices declined by over $1 per kg, with Chinese competition remaining a persistent drag. Long-term customer relationships and world-scale capacity allowed the company to run facilities almost at full capacity.
- Spot margins bottomed out but thin: Management believes spot business prices and margins have reached a floor; any raw material cost reduction will trigger further price declines, so the current spot margin is not thick.
- Strategic pivot to regulated pharma customers: The company is actively changing its customer profile toward regulatory-oriented buyers who pay higher prices, aiming to cap spot volume at 30–40% of total even as capacity expands from 5,000 to 9,000 metric tonnes.
- Regulatory filings to unlock that pivot: A DMF and EUGMP CEP filing from the Tarapur unit three plant will be submitted in the current quarter, enabling penetration into regulated pharmaceutical markets from a second location currently used only for spot sales.
- Capacity expansion in two phases: The brownfield expansion to 9,000 MT will come online in the first half and second half of FY26; management is hopeful of reaching 90% capacity utilization in FY27.
- US tariff tailwind: A 10% additional US duty on Chinese goods will apply to caffeine, and management is "fairly hopeful" this will help expand absolute volumes from the higher capacity base.
Gogri: "Aarti Pharma Labs is positioned in such a way that it has a global size, it has a risk mitigation strategy, which doesn't depend on China at all."
CDMO/CMO: Pipeline Converting, Capacity Ready
- Inflection in commercial projects: Growth is coming primarily from projects reaching commercialization, not small development-phase work. Two new customers were added this quarter, and the company will exceed last year's Rs.170 crore CDMO/CMO revenue in the current quarter.
- FY26 set to be significantly higher: Independent of any orders shifted from Q4 by the Vapi shutdown, next year's CDMO/CMO number will be "significantly higher" because the pipeline is shaping up well, with a sizable order book already in hand for the next financial year.
- Backward integration as a differentiator: The company can execute four, five, or six synthesis stages in-house, allowing it to propose maximum steps in India with minimal China dependency, a pitch that resonates with innovators.
- Capacity built to scale: The first block at the dedicated CDMO site is operational, with space to add more than 10 additional blocks. Future blocks can be built at significantly lower investment and within a year.
- Vapi shutdown caused a minor push: A temporary two-week plant closure in January, triggered by a State Pollution Control Board notice, may shift some CDMO/CMO sales originally scheduled for Q4 into the next quarter. The impact is less than 5% of turnover and 2% of profit, with no long-term consequence.
Gogri: "We can do backward integrated work also so, we can do four, five, six stages in-house. So we are able to give a proposal to innovators that we will try to do maximum steps in India only and having least dependency on China."
API & Intermediates: Volume-Led Growth, Regulated-Market Tilt
- Best quarterly revenue performance: The API and intermediates segment delivered its highest-ever quarterly revenue, with 27% YoY growth in the first nine months driven by demand and capacity expansion.
- Tarapur expansion running full: Block 5 at the Tarapur API site is operating at full capacity, and one additional line is being added for another ~10% capacity. The site can deliver Rs.800–1,000 crore of revenue depending on product mix, with room for an additional 300–400 KL of capacity within a year.
- Anti-hypertensive launch a standout: One significant successful launch in the anti-hypertensive segment contributed materially to growth. The three large therapy categories are anti-hypertensives (the largest), steroids, and anti-cancer, supplemented by CMS therapeutic areas.
- Mix shifting toward regulated markets: API and intermediates share of total revenue rose from 37% in FY23 to 46% in the nine-month period, aligned with a long-term focus on regulated markets. ROW markets like Brazil, Russia, and China sometimes offer better pricing than the US and Europe.
- Generic pricing is structurally deflationary: In the generic market, prices never rise even in rupee terms except when a product becomes extremely commoditized at rock bottom, so constant R&D and cost savings are required to offset erosion.
- Pipeline depth: 12 new APIs are under development, with newer anti-cancer and general block products launching next year, and a good pipeline of products to be commercialized over the next two to three years.
Gogri: "In the generic market, I have never seen prices go up even in rupee terms, except the product become extremely genericized, and you are at the rock bottom."
Margins: Record Quarter, Sustainability Questions
- Standalone EBITDA margin reached ~24%: This was 200–300 bps above the prior two quarters, making it a record quarter. The step-up was driven by a significant CDMO/CMO sales contribution (which had been lower in the previous two quarters), activation of the 21 MW solar project generating savings, and Rs.7 crore of dividend income accrued this quarter.
- Replicability is the open question: Management is "hopeful" of replicating the performance but cautioned there will be no linearity, with ups and downs expected. The dividend income is non-recurring, and CDMO/CMO sales can be lumpy quarter to quarter.
- Solar and fuel savings building structurally: The 21 MW DC solar project at Akola is operating as expected, and a second 9 MW DC captive project for Gujarat units will likely commission in Q2 FY26. Combined, these are estimated to generate more than half of total electricity requirements. Solid multi-fuel boilers starting at two Maharashtra plants in Q4 FY25 will cut fuel costs and carbon footprint by using bio-briquettes for all steam needs.
- Ganesh Polychem contributed ~Rs.13 crore: The 50:50 JV with the Bandodkar family added roughly Rs.13 crore to consolidated EBITDA this quarter (Aarti's share), explaining a material portion of the consolidated vs. standalone gap.
Gogri: "We are hopeful that we are able to replicate these kind of performance in future quarters as well. But of course, we can't have a certain linearity there will be ups and downs, but overall, we will see a growth going."
Capacity & Infrastructure: Two Large Projects Advancing
- Xanthine brownfield expansion (5,000 to 9,000 MT): Progressing as planned, with regulatory filings for the Tarapur unit three plant due in the current quarter. The capacity will be added in two phases across the first and second halves of FY26, with 90% utilization targeted for FY27.
- Atali greenfield project: Phase-1 is expected to be commissioned in Q1 FY26 with ramp-up toward the end of FY26. The site is designed to facilitate pilot-to-commercial scale-up within the same block. Regulatory audits and commercial triggers will primarily occur in FY26, but full ramp-up will take two-plus years. Management expects 1 to 1.25x asset turn once significant capacity is occupied.
- CDMO site scalable at low incremental cost: The first block is operational; more than 10 additional blocks can be added, with future blocks built at significantly lower investment and within a year.
- R&D infrastructure: Three R&D centers are operating: one exclusively for innovators, one focused on the API business, and a third for scale-up and raw-material-saving idea generation. 58 patents have been filed.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 EBITDA growth | May exceed previously provided 10–12% growth guidance | FY25 (verifiable at Q4) |
| CDMO/CMO FY25 revenue | Will exceed last year's Rs.170 crore in the current quarter | Q4 FY25 |
| CDMO/CMO FY26 revenue | Will be "significantly higher" than FY25, independent of shifted orders | FY26 |
| Xanthine capacity expansion | 5,000 to 9,000 MT in two phases | H1 and H2 FY26 |
| Xanthine utilization target | 90% capacity utilization | FY27 |
| Atali Phase-1 commissioning | Commissioning in Q1, ramp-up toward end of FY26 | Q1 FY26 / end FY26 |
| Second solar project (9 MW DC) | Commissioning for Gujarat units | Q2 FY26 |
| Solid multi-fuel boilers | Starting at two Maharashtra plants | Q4 FY25 |
| Xanthine regulatory filings | DMF and EUGMP CEP from Tarapur unit three | Current quarter (Q4 FY25) |
| Long-term guidance reset | Full budgeting, strategic review, yearly and three-year guidance | Q4 FY25 concall |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated revenue | ₹538 cr, +20% YoY |
| EBITDA | ₹129 cr, +34% YoY |
| Profit after tax | ₹74 cr, +40% YoY |
| Standalone EBITDA margin | ~24%, 200–300 bps higher than previous two quarters |
| FY25 EBITDA growth guidance | Exceeding 10–12% previously guided |
| Xanthine derivatives revenue share | 44% of turnover |
| API and intermediates revenue share | 42% of turnover; sub-segment: 48% regulated, 40% ROW, 12% non-reg |
| CDMO/CMO revenue share | 13% of turnover |
| CDMO/CMO active projects | 56 projects, 28 commercial and 28 in development |
| CDMO/CMO customers | 21 customers, 2 added in Q3 |
| API quarterly revenue run rate | ₹203 cr, up from ₹150 cr a year ago |
| API capacity utilization | ~75%, with 10% additional capacity being added |
| Xanthine spot market volume share | 30–40% of total volume |
| Vapi plant shutdown impact | Lower than 5% of turnover and 2% of profit |
| Ganesh Polychem EBITDA contribution (50% share) | ₹13 cr in Q3, vs ₹9 cr last quarter |